Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desogestrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 6/20 | 1.00 |
| ▸ | SHBG | P04278 | 8/20 | 1.00 |
| ▸ | ESR1 | P03372 | 6/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 6/20 | 1.00 |
| ▸ | AR | P10275 | 4/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | CCKBR | P32239 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desogestrel SCHEMBL14071563 | 1.00 | SHBG (1.00) | SHBGPGRESR1SLC6A4AR | |
| Desogestrel SCHEMBL41341 | 1.00 | SHBG (1.00) | SHBGPGRESR1SLC6A4AR | |
| Desogestrel SCHEMBL13575760 | 1.00 | SHBG (1.00) | SHBGPGRESR1SLC6A4AR | |
| Desogestrel SCHEMBL28425701 | 0.95 | SHBG (0.90) | SHBGPGRESR1SLC6A4AR | |
| Etonogestrel SCHEMBL14941286 | 0.92 | SHBG (0.87) | SHBGPGRESR1SLC6A4AR | |
| Desogestrel SCHEMBL8853428 | 0.91 | SHBG (0.82) | SHBGPGRESR1SLC6A4AR | |
| SCHEMBL11335079 | 0.89 | SHBG (0.79) | SHBGPGRESR1SLC6A4AR | |
| SCHEMBL10933534 | 0.89 | SHBG (0.79) | SHBGPGRESR1SLC6A4AR | |
| Etonogestrel SCHEMBL8731710 | 0.88 | PGR (0.79) | SHBGPGRESR1SLC6A4AR | |
| SCHEMBL16421288 | 0.87 | PGR (0.76) | SHBGPGRESR1SLC6A4AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10864220-B2 | Applications of desogestrel in the preparation of anti-colon cancer/breast cancer ER-negative Ah receptor-positive products | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2020-12-15 | — | — | US | disclosed |
| US-20180185387-A1 | APPLICATIONS OF DESOGESTREL IN THE PREPARATION OF ANTI-COLON CANCER/BREAST CANCER ER-NEGATIVE AH RECEPTOR-POSITIVE PRODUCTS | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185387-A1 | APPLICATIONS OF DESOGESTREL IN THE PREPARATION OF ANTI-COLON CANCER/BREAST CANCER ER-NEGATIVE AH RECEPTOR-POSITIVE PRODUCTS | FSHR, GPER1, PGR | PGR 3/4885SHBG 50/4885ESR1 4/4885 |
| US-10864220-B2 | Applications of desogestrel in the preparation of anti-colon cancer/breast cancer ER-negative Ah receptor-positive products | FSHR, GPER1, PGR | PGR 3/4885SHBG 50/4885ESR1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.